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Abstract: 
 
Deferred active treatment (DAT) strategies, including active surveillance and active 
monitoring, are a recognised management option for men with localised low-risk 
prostate cancer. However, there is uncertainty due to heterogeneity of patient selection 
criteria, follow-up and monitoring characteristics, reclassification thresholds, and which 
outcome measures should be prioritised. This protocol describes a study led by the 
European Association of Urology (EAU) Prostate Cancer Guidelines Panel in 
conjunction with other guideline organisations and societies* to develop consensus 
statements for all domains of deferred active treatment. The project is divided into 3 
sequential phases: (1) Systematic review of studies reporting on DAT in order to 
summarise and define range of heterogeneity regarding all domains; (2) Two-round 
Delphi online survey involving a large, international panel of healthcare professionals 
(HCPs) and patients to initiate consensus; and (3) Consensus group meeting involving 
representatives from HCP and patient stakeholder groups to finalise the consensus 
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process. The consensus statements are expected to be adopted by clinical practice 
guidelines in order to standardise and guide practice for clinicians and researchers 
until better evidence emerges. 
Patient summary: We describe a project aimed at standardising elements of practice 
in active surveillance/monitoring for early localised prostate cancer, because currently 
there is great variation and uncertainty regarding how best to conduct them. This will 
be achieved through a structured process of agreement (i.e. consensus) amongst a 
large, international panel of healthcare professionals and patients.     
 
 
Deferred active treatment (DAT) strategies for men with localised prostate cancer have 
emerged as a viable alternative to radical intervention as we aim to avoid the 
consequences of over-treatment. Nevertheless, such strategies remain controversial, 
with significant uncertainty and heterogeneity in all domains, including criteria on 
patient selection, nature and timing of interventions during follow-up, criteria and 
thresholds for reclassification, and which outcome measures should be prioritised1-3. 
These are important barriers to the conduct and uptake of DAT by clinicians and 
patients, and makes it extremely difficult to compare the clinical effectiveness of 
different protocols against each other. In order to address these issues in a 
comprehensive, robust and systematic manner, the EAU Prostate Cancer Guidelines 
Panel, in partnership with other leading guideline authorities and societies*, has 
commissioned a project to develop consensus statements in all domains relating to 
DAT in order to standardise clinical practice and research.  
 
The specific objectives are to achieve consensus on the following domains: (1) Criteria 
on patient selection (including patient and disease characteristics, imaging criteria and 
type of biopsies); (2) Nature and timing of interventions during follow-up (such as 
repeat imaging and repeat biopsies); (3) Criteria and thresholds for reclassification; 
and (4) Type of outcome measures which should be prioritised.  
To address these objectives, we will utilise transparent consensus methods 
involving a large, international cohort of stakeholders, broadly divided into two groups: 
(1) Healthcare professionals (HCPs) consisting of urologists, clinical or radiation 
oncologists, medical oncologists, radiologists, pathologists, primary care physicians,  
and nurse specialists; and (2) Patients.  The research will be divided into 3 distinct but 
inter-related phases, and is expected to last 12 months.   
 
Phase 1 is a systematic review conducted according to PRISMA guidelines4. The aim 
to describe, explore and assess clinical heterogeneity in DAT studies which will inform 
the statements for the consensus processes. The review protocol has been published5. 
In brief, all prospective single-arm case series of DAT (including active surveillance 
and active monitoring but excluding watchful waiting), and all prospective comparative 
studies involving DAT will be included. The review will summarise eligibility and 
selection criteria, characteristics of monitoring and follow-up (including the type, 
frequency and timing of repeat imaging and repeat biopsies), reclassification 
definitions and thresholds, and primary outcomes measured in studies. English 
language articles published after 1990 will be included. Summary of findings tables 
including details of the pre-specified domains and sub-domains will be developed. 
From these tables, a list of statements organised according to the different domains 
and sub-domains relating to all aspects of DAT will be generated. 
 
Phase 2 will comprise of a two-round online Delphi survey involving a large, 
international cohort of key stakeholders (HCPs and patients). The consensus methods 
used have been described previously in consensus studies in prostate cancer6,7. HCPs 
involved with DAT identified through international specialist societies* will be invited to 
participate. Patients throughout Europe with localised prostate cancer and eligible for 
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DAT will be recruited through patient charities*. Up to 200 HCPs and 100 patients will 
be invited to participate. Patients will be asked to complete the patient-relevant parts 
of the survey only (i.e. identification of most important outcomes). Participants will be 
asked to vote based on their level of agreement, on a nine-point scale, ranging from 
strongly disagree (1) to strongly agree (9) (i.e. 1–3 disagree; 4–6 uncertain; 7–9 agree). 
There will also be an ‘Unable to answer’ option. An online questionnaire will be 
developed for the Delphi process using COMET Initiative DelphiManager8. Two 
iterative rounds will be conducted anonymously, with anonymised feedback provided 
to all participants at the end of each round showing the percent scoring at each 
response option. In Round 1, participants will have the opportunity to add further 
statements for incorporation into Round 2. With an anticipated response rate of 80% 
for both stakeholder groups, and expected completion rate of 60% for both rounds, the 
total number of participants involved is expected to be 144 (i.e. 96 HCPs and 48 
patients). The results for each stakeholder group will be analysed and presented 
separately in each round. After the final round, statements scoring ‘strongly agree’ (i.e. 
7–9) by ≥70% of participants AND with minimal disagreement scored by the rest 
(defined as <15% of participants scoring ‘strongly disagree’ i.e. 1-3) will be considered 
as reaching the threshold for ‘consensus agree’. Conversely, statements scoring 
‘strongly disagree’ (i.e. 1-3) by ≥70% of participants AND with minimal agreement 
scored by the rest (defined as <15% of participants scoring ‘strongly agree’ i.e. 7-9) 
will be considered as reaching the threshold for ‘consensus disagree’. All other 
statements not falling in the above categories will be classified as ‘equivocal’. 
Statements reaching consensus (either agree or disagree) will be collated for review 
in Phase 3, whilst equivocal statements will be brought forward for discussion and 
voting in Phase 3. 
 
Phase 3 is the final stage of the consensus process, involving a 1-day meeting 
attended by representatives of each stakeholder group and chaired by a non-voting 
methodologist and a clinician moderator. We will use structured discussion and live 
voting sessions. Representatives from each stakeholder groups and sub-groups (i.e. 
urologists, oncologists, radiologists, pathologists and patients) will be purposively 
sampled from those completing all rounds of the Delphi survey to ensure proportional 
representation. The voting panel will consist of 25 voting participants (i.e. 7 patients 
and 18 HCPs). Statements reaching consensus (either agree or disagree) from Phase 
2 will be reviewed by the panel. Consensus decisions from the Delphi survey cannot 
be overturned by the panel without sound reasoning (e.g. misleading statements). 
Equivocal statements from Phase 2 will be discussed and voted on by the panel. 
Scoring thresholds will be the same as Phase 2 (i.e. level of agreement on a nine-point 
scale: 1–3 disagree; 4–6 uncertain; 7–9 agree; and ‘Unable to answer’). Voting will be 
anonymous using Poll Everywhere9 which participants can access during the meeting 
using personal computers and a shared IP address. Definitions of consensus will be 
the same as in Phase 2. Results for all statements will be conveyed in real-time, and 
final consensus statements will be prepared. A final list of consensus statements 
organised according to the domains and sub-domains of DAT will be issued.  
 
The consensus statements are expected to be adopted by guideline developers and 
disseminated through clinical practice guidelines issued by the EAU Prostate Cancer 
Guidelines Panel and other organisations*, and are intended to provide authoritative 
guidance to clinicians and researchers by standardising definitions, thresholds, 
terminology and characteristics of patient selection, monitoring, reclassification and 
change in management, and outcome measures which should be prioritised in 
programmes of deferred active treatment in clinical practice and research, at least until 
higher levels of evidence emerge such as from the GAP3 initiative10.  
 
* The list of official collaborators include the following organisations and patient-led societies:  
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European Association of Urology (EAU) 
European Association of Urology Nurses (EAUN) 
EAU PIONEER  
European Urology 
American Urological Association (AUA) 
Canadian Urological Association (CUA) 
European Society for Radiotherapy and Oncology (ESTRO) 
International Society of Urological Pathology (ISUP) 
Urological Society of Australia and New Zealand (USANZ) 
European Society of Urogenital Radiology (ESUR) 
EAU Section of Oncological Urology (ESOU) 
Urological Association of Asia (UAA) 
American Society for Radiation Oncology (ASTRO) 
American Society of Clinical Oncology (ASCO) 
European Forum for Primary Care (EFPC) 
EAU Research Foundation (EAU RF) 
UCAN UK 
Tackle Prostate Cancer UK 
Europa UOMO  
Movember Foundation 
 
 
References 
 
1. Bruinsma, S.M., et al. Expert consensus document: Semantics in active 
surveillance for men with localized prostate cancer - results of a modified Delphi 
consensus procedure. Nat Rev Urol, 2017. 14: 312..  
2. Mottet, N., Van den Bergh, RCN, Briers, E, Bourke, L, Cornford, P, De Santis, 
M, Gillessen, S, Govorov, A, Grummet, J, Henry, AM, Lam, TB, Mason, MD, 
van der Poel, HG, van der Kwast TH, Rouviere, O, Wiegel, T., EAU-ESTRO-
ESUR-SIOG Guidelines on Prostate Cancer E.G. Office, Editor. 2018, 
European Association of Urology: Arnhem, The Netherlands 
3. Donovan JL, Hamdy FC. Time for a "Radical" Change to Active Surveillance 
for Prostate Cancer? Eur Urol. 2018 Sep;74(3):281-282. doi: 
10.1016/j.eururo.2018.05.009. Epub 2018 May 17. PMID: 297798604. 
4. Moher, D., et al. Preferred reporting items for systematic reviews and meta-
analyses: the PRISMA statement. PLoS Med, 2009. 6: e1000097. 
5.  Willemse, P., Lam, T, Mottet, N, Yuan, C, Donaldson J, Davis, N, Dell'Oglio, P, 
Fankhauser, C, Grivas, N, Ingels, A, Lardas, M, Liew, M, Pang, K, Paterson, 
C, Omar, I, Zattoni, F, Buddinh, T. Systematic review of deferred treatment with 
curative intent for localised prostate cancer to explore heterogeneity of 
definitions, thresholds and criteria and clinical effectiveness. 2018. 
6. MacLennan, S., et al. A core outcome set for localised prostate cancer 
effectiveness trials. BJU Int, 2017. 120: E64. 
7. van der Poel, H.G., et al. Sentinel node biopsy for prostate cancer: report from 
a consensus panel meeting. BJU Int, 2017. 120: 204. 
8. COMET Initiative DelphiManager. 2018. 
9. Everywhere, P. Poll Everywhere. https://www.polleverywhere.com  
10. Bruinsma SM, Zhang L, Roobol MJ, Bangma CH, Steyerberg EW, Nieboer D, 
Van Hemelrijck M; Movember Foundation's Global Action Plan Prostate Cancer 
Active Surveillance (GAP3) consortium. The Movember Foundation's GAP3 
cohort: a profile of the largest global prostate cancer active surveillance 
database to date. BJU Int. 2018 May;121(5):737-744. doi: 10.1111/bju.14106. 
 
 
 
